Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

Nobuaki Sato; Norikazu Masuda; Takashi Morimoto; Takayuki Ueno; Chizuko Kanbayashi; Koji Kaneko; Hiroyuki Yasojima; Shigehira Saji; Hironobu Sasano; Satoshi Morita; Shinji Ohno; Masakazu Toi

doi:10.1002/cam4.2423

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

Cancer Medicine ◽

10.1002/cam4.2423 ◽

2019 ◽

Vol 8 (12) ◽

pp. 5468-5481

Author(s):

Nobuaki Sato ◽

Norikazu Masuda ◽

Takashi Morimoto ◽

Takayuki Ueno ◽

Chizuko Kanbayashi ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase Ii ◽

Phase Ii Study ◽

Open Label ◽

Estrogen Receptor Positive ◽

Open Label Phase ◽

Positive Breast Cancer

Download Full-text

Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study

Cancer Medicine ◽

10.1002/cam4.1600 ◽

2018 ◽

Vol 7 (7) ◽

pp. 3044-3056 ◽

Cited By ~ 6

Author(s):

Nobuaki Sato ◽

Norikazu Masuda ◽

Takashi Morimoto ◽

Takayuki Ueno ◽

Chizuko Kanbayashi ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Combination Therapy ◽

Low Dose ◽

Phase Ii Study ◽

Neoadjuvant Endocrine Therapy ◽

Open Label ◽

Estrogen Receptor Positive ◽

Open Label Phase ◽

Positive Breast Cancer

Download Full-text

A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-017-4199-3 ◽

2017 ◽

Vol 163 (3) ◽

pp. 535-544 ◽

Cited By ~ 9

Author(s):

José Baselga ◽

Serafin M. Morales ◽

Ahmad Awada ◽

Joanne L. Blum ◽

Antoinette R. Tan ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase Ii ◽

Phase Ii Study ◽

Estrogen Receptor Positive ◽

Positive Breast Cancer

Download Full-text

Abstract P3-11-04: A phase II study of pembrolizumab, letrozole and palbociclib in patients with metastatic estrogen receptor positive breast cancer

10.1158/1538-7445.sabcs19-p3-11-04 ◽

2020 ◽

Author(s):

Yuan Yuan ◽

Susan E Yost ◽

Jin Sun Lee ◽

Colt Egelston ◽

Paul H Frankel ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase Ii ◽

Phase Ii Study ◽

Estrogen Receptor Positive ◽

Positive Breast Cancer

Download Full-text

Abstract P4-02-19: A Phase II Study of Adding the Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients with Metastatic Estrogen Receptor Positive Breast Cancer

10.1158/0008-5472.sabcs10-p4-02-19 ◽

2010 ◽

Cited By ~ 2

Author(s):

J Moss ◽

M Stevens ◽

S Birk ◽

K Westberry ◽

E Romond ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Endocrine Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Multikinase Inhibitor ◽

Estrogen Receptor Positive ◽

Positive Breast Cancer

Download Full-text

Faculty Opinions recommendation of Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734565867.793581155 ◽

2020 ◽

Author(s):

David Potter

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Neoadjuvant Therapy ◽

Early Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Estrogen Receptor Positive

Download Full-text

179P Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin for early triple-negative breast cancer: A single-arm, open-label, phase II study

Annals of Oncology ◽

10.1016/j.annonc.2021.08.460 ◽

2021 ◽

Vol 32 ◽

pp. S436

Author(s):

C. Wang ◽

Z. Liu ◽

X. Chen ◽

J. Qiao ◽

L. Li ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Study ◽

Open Label ◽

Open Label Phase

Download Full-text

Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor–Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial

Journal of Nuclear Medicine ◽

10.2967/jnumed.117.194654 ◽

2017 ◽

Vol 59 (2) ◽

pp. 197-203 ◽

Cited By ~ 12

Author(s):

Michel Paquette ◽

Éric Lavallée ◽

Serge Phoenix ◽

René Ouellet ◽

Helena Senta ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Estrogen Receptor ◽

Cancer Patients ◽

Phase Ii ◽

The Novel ◽

Breast Cancer Patients ◽

Estrogen Receptor Positive ◽

Ongoing Phase ◽

Positive Breast Cancer

Download Full-text

Randomised Phase Ii Study Evaluating, As First-Line Chemotherapy, Weekly Oral Vinorelbine As a Single-Agent Versus Weekly Paclitaxel As a Single-Agent in Estrogen Receptor Positive, Her2-Negative Patients with Advanced Breast Cancer (Norbreast-231 Trial)

Annals of Oncology ◽

10.1093/annonc/mdu329.63 ◽

2014 ◽

Vol 25 ◽

pp. iv136

Author(s):

M. Aapro ◽

E. Staroslawska ◽

S. Morales ◽

M. Ruiz Borrego ◽

S. Cinieri ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

First Line ◽

Oral Vinorelbine ◽

Estrogen Receptor Positive ◽

Line Chemotherapy

Download Full-text

A Phase II Study (FINDER 2) Comparing Three Dosing Regimens of Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer.

10.1158/0008-5472.sabcs-09-4095 ◽

2009 ◽

Author(s):

K. Pritchard ◽

J. Rolski ◽

Z. Pápai ◽

L. Mauriac ◽

F. Cardoso ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Breast ◽

Estrogen Receptor Positive ◽

Dosing Regimens

Download Full-text

Abstract GS2-07: MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer

10.1158/1538-7445.sabcs17-gs2-07 ◽

2018 ◽

Cited By ~ 9

Author(s):

P Schmid ◽

M Zaiss ◽

C Harper-Wynne ◽

M Ferreira ◽

S Dubey ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Mtor Inhibitor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Estrogen Receptor Positive

Download Full-text